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Radiotherapy for pericardial involvement of multiple myeloma. A case report
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Introduction. Pericardium involvement is unusual in Multiple myeloma (MM) (0.5%), with less than 25 cases recorded in rele-
vant literature. It is associated with poor prognosis. Treatment options described in the literature are pericardiocentesis with
intrapericardial bleomycin, and chemotherapy with very low response rates.
Case report. 67 year oldmale diagnosed in 2001withmultiplemyelomaBence-JonesKappa stage IIIB. Initial complete responsewas
obtained after treatment with VBCMP/VBAD and auto-TPH. In 2006 and 2008 progressions of MM were treated with three more
lines of chemotherapywith ﬁnal complete remission. In 2011, patient presented cardiogenic syncope and pericardial effusionwas
observed on transesophageal echocardiography (TEE). Twomonths later, CT scan andTEE showedpericardial effusionprogression
with heart cavities partial collapse. Pericadiocentesis was performed, and cytologyc examination revealed clearly plasma cells.
Subsequently, an instillation of intrapericardial bleomycin and systemic treatment with lenalidomide were performed. Later
TEE showed residual pericardial effusion and discontinuities in the edges of the pulmonary artery, suggesting mediastinic-
pericardial mass, conﬁrmed by MRI scan. The patient was referred to our department, where external beam radiotherapy on
the mass to a total dose of 30Gy by 3Gy per fraction was performed. In later revisions, MRI scan and TEE showed pericardial
effusion decreased and a marked shrinkaged of the cardiac lesion. Disease progressed to the kidney with the patient ultimately
suffering renal failure with hydroelectrolytic imbalance and medullary aplasia secondary to chemotherapy which resulted in
sepsis, leading to the death of the patient two months later.
Conclusion. Pericardial involvement by MM can generate a pericardial effusion that can evolve into pericardial tamponade, with a
very poor prognosis. In current publications there are no references to external radiotherapy as a treatment option. In this case
we used radiotherapy with favorable local results.
http://dx.doi.org/10.1016/j.rpor.2013.03.345
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Introduction. Primary small bowel non-Hodgkin lymphoma is uncommon. Primary gastrointestinal non-Hodgkin lymphoma is
4–20% of all lymphomas and small bowel lymphoma is 20–54% of all gastrointestinal non-Hodgkin lymphomas.
Methods. A 62 year-oldwomanpresentedwith abdominal pain and constipation asmain symptoms. She did not have B symptoms.
The patient underwent endoscopy with duodenal biopsy. The histologic ﬁndings shows low-grade follicular lymphoma. She
completed study with body CT and bone marrow biopsy. After endoscopic biopsy the patient was treated with three-dimensional
conformal radiation therapy. The ﬁeld included the volved duodenal portion, to a total dose of 30Gy (5×2Gy).
Results. The most common treatment has been surgical resection followed adjuvant chemotherapy, radiotherapy or both. This
case was an indolent disease and the patient preferred radiotherapy alone and delayed chemotherapy only in case of relapse.
With 9 months of follow-up, the patient is free of disease. She underwent endoscopy with biopsy four months after the treatment
and the histologic ﬁnding was negative. Acute side effect was grade I nausea and vomiting. The patient does not have late toxicity.
Conclusion. Radiation therapy for small bowel lymphoma is well tolerated and gives good local control. However to carry out this
treatment the lesion have to locate in a no mobile small bowel portion. Some lesions cannot be located by CT imaging, in this
cases ﬁducial markers placed during the endoscopy could help us to planning the treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.346
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Introduction. Orbital lymphomas constitute about 8% of extranodal lymphomas and 1% of NHL, usually affecting conjunctiva and
eyelids and rarely retrobulbar region. Optimal treatment is yet to be determined. RT, frequently used, is a treatment that offers
excellent local response rates allowing organ preservation.
Method. 74 year old male with clinical three-month history of mild left proptosis and diplopia. On examination was observed left
VI cranial nerve paresis and exophthalmos. Normal visual acuity and fundus. Orbits CT and MRI describes a 15×12×6mm left
intraorbital mass perfectly deﬁned, occupying half inferior orbital, hypointense, that contacts the posterior, temporal and inferior
pole of the eyeball (inferior rectus, inferior oblique and lacrimal gland) without inﬁltration signs. Transconjunctival approach to
left periorbital incisional biopsy was performed with pathology result: connective tissue inﬁltration by Marginal zone lymphoma
ofmucosa-associated lymphoid tissue (MALT). The patientwas treatedwith 3D conformal radiotherapywith TC support (1.25mm
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S275–S281 S281
interval sections) and diagnostic MRI image fusion. CTV was left orbit using two 6MV wedges oblique-ﬁelds. A total dose of 27Gy
in 15 fractions was administered. Tolerance to treatment was adequate, with mild transient epiphora and conjunctivitis. Result:
two months after treatment there was a complete clinical and radiological response without any toxicity associated.
Conclusions. There are no data from randomized trials on which to base therapeutic decisions, however, numerous retrospective
studies show that RT offers excellent local control rates and cause-speciﬁc survival at doses up to 30Gy allowing preserve the
orbital integrity with very low risk of severe complications. Other treatment options include complete excision of small lesions,
intralesional interferon alpha or observation. Eradication of Chlamydia Psitttaci, whoseDNAhas been found in some conjunctival
MALT, with doxycycline, showed partial and even complete responses in some series.
http://dx.doi.org/10.1016/j.rpor.2013.03.347
Total body irradiation (TBI) institutional experience
A. Fondevilla1, C. Castilla-llorente2, M. Dzhugashvili 1, P. Sempere1, I. Heras2, F. de Arriba3
1 IOSE – Instituto Oncólógico del Sureste, Grupo IMO, Unidad Regional de Murcia, Spain
2 Hospital General Universitario J.M. Morales Meseguer, Servicio de Hematologia, Spain
3 Hospital General Universitario de Murcia, Servicio de Hematologia, Spain
Purpose. Was analyzed our experience in patients with hematological diseases who underwent myeloablative transplant with
TBI and cyclophosphamide as part as the conditioning regimen.
Patients and methods. Retrospective study of 43 patients (17 female, 26 males) from October 2006 to December 2011 underwent
transplantation with TBI as part of the conditioning regimen (42 allogeneic transplant and 1 autologous transplant). The haema-
tological disease was acute leukaemie in 35 patients (81%), NHL in 3 (7%) and others in 5 patients (12%). The dose of TBI were
12Gy in 6 fractions, twice a day with an interval at least of 6h. No patient received more than 10Gy in lungs. The administration
of the treatment was performed on a linear accelerator, energy of 15MV a source to patient’s middle line distance of 5m. The
patients are inmovilized in supine position. The skin dose is increased using a large plastic screen (methacrylate) covering the
whole body and is placed approximately 10 cm from the patient, which acts as a source of scattered electrons. We analyzed the
incidence of acute transplant related toxicity (before day +90) and overall survival (OS), transplant related mortality (TRM) and
disease free survival (DFS). Results: Acute transplant toxicity incidence was: grade >3 mucositis 29 cases (67%), acute parotidis 7
cases (16%) and grade >3 nausea or vomit in 2 case (5%). Day +100 TRM, OS and DFS were 2%, 98% and 100% respectively. With a
median follow up of 44 months (range 1–85), 32 patients (74%) are alive and in complete remission of their underlying disease, 8
patients (19%) died of disease relapse or progression and 2 patients of TRM.
Conclusions. DFS and toxicity are successfully compared to literature data.
http://dx.doi.org/10.1016/j.rpor.2013.03.348
